[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363943-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-363943-en":123},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","b7-h3-cd276-an-actionable-therapeutic-target-and-prognostic-biomarker-across-human-malignancies","B7-H3 (CD276) - an actionable therapeutic target and prognostic biomarker across human malignancies","","Immune checkpoint protein B7-H3 (CD276) is increasingly recognized as a cancer immunotherapy target and biomarker. Although no definitively identified receptor is available, B7-H3 is implicated in multiple tumor progression mechanisms, is overexpressed across many cancer types, and is frequently linked to poor prognosis. Current immunotherapeutic approaches include antibody-based strategies, CAR-T cells, and bispecific antibodies, with clinical trials ongoing in diverse malignancies. This review summarizes present knowledge on B7-H3 biology and therapy development, while emphasizing the need for further research into its regulation, mechanisms, and associated pathways.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/b7-h3-cd276-an-actionable-therapeutic-target-and-prognostic-biomarker-across-human-malignancies/363943/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/b7-h3-cd276-an-actionable-therapeutic-target-and-prognostic-biomarker-across-human-malignancies/363943.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"What role does the B7 family play in immune regulation?","Question",{"text":63,"@type":64},"The B7 family provides costimulatory or coinhibitory signals that act as “second signals” in the two-signal model for naïve lymphocytes. They tune lymphocyte activation to shape the final immune response and maintain immune homeostasis.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},363943,1790198529,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,107,112,115,119],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":104,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":105,"slug":106},8,30,"research-report",{"id":108,"doc_module":4,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},9,"Religion & Spirituality",20,"religion-spirituality",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":113,"show_sort_weight":110,"slug":114},"World Cup","world-cup",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":116,"slug":118},10,"Lifestyle","lifestyle",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":89,"slug":122},19,"General","general",{"code":4,"msg":74,"data":124},{"doc_id":71,"user_id":125,"nickname":42,"user_avatar":126,"doc_module":4,"category_id":104,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":120,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":33,"preview_urls":138},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 17 July 2026  \nDOI 10.3389/fimmu.2026.1857767  \nOPEN ACCESS  \nEDITED BY  \nEyad Elkord,  \nXi’an Jiaotong-Liverpool University, China  \nREVIEWED BY  \nNick Devoogdt,  \nVrije University Brussels, Belgium Cyprine Neba Funeh,  \nInstitute of Cancer Research (ICR), United Kingdom  \n*CORRESPONDENCE  \nVenkata Lokesh Battula  \n [battulav3@vcu.edu](battulav3@vcu.edu)  \nRECEIVED 16 April 2026  \nREVISED 10 June 2026  \nACCEPTED 15 June 2026  \nPUBLISHED 17 July 2026  \nCITATION  \nSmith D, Tyagi A and Battula VL (2026) B7-H3 (CD276): an actionable therapeutic target and prognostic biomarker across human malignancies. Front. Immunol. 17:1857767 .  \ndoi: 10.3389/fimmu.2026.1857767  \nCOPYRIGHT  \n© 2026 Smith, Tyagi and Battula. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nB7-H3 (CD276): an actionable therapeutic target and prognostic biomarker across human malignancies  \nDayna Smith 1, Anudishi Tyagi 2 and Venkata Lokesh Battula 2* 1 Research Institute of Molecular Pathology, Vienna, Austria, 2 Department of Internal Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, United States  \nImmune checkpoint protein B7-H3 (CD276) has garnered increasing attention asa cancer immunotherapy target. Despite the absence of a deﬁnitively identiﬁed receptor, B7-H3 is implicated in multiple mechanisms of tumor progression. As a cancer biomarker, it is overexpressed in numerous cancer types and is often associated with poor prognosis. B7-H3 is currently the target of numerous immunotherapeutic strategies, and clinical trials are underway in various cancer types. This review provides an updated summary of the current body of knowledge regarding immune checkpoint protein B7-H3 and cancer therapies targeting it, highlighting its demonstrated promise as a cancer immunotherapy target, the need for further investigation into the regulation and mechanisms of B7-H3 and its associated pathways, and therapeutic progress.  \nKEYWORDS  \nantibody-drug conjugates (ADCs), B7-H3, cancer immunotherapy, CAR-T cells and bispeciﬁc antibodies, immune checkpoint protein (ICP)  \nIntroduction  \nImmunotherapy, either alone or in combination with conventional therapies like radiation or chemotherapy, represents a transformative approach in cancer treatment. Among immunotherapeutic strategies, the targeting of immune checkpoint proteins (ICPs) has demonstrated remarkable clinical success. Notable inhibitory checkpoints, including programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), act as key regulators of immune activation but are frequently exploited by tumor cells to evade immune surveillance through altered expression (1) . Inhibition of immunosuppressive ICPs by immune checkpoint inhibitors (ICIs) counteracts this suppression, restoring antitumor immunity and producing durable clinical responses in various malignancies (2). Among approved immunotherapies, ICIs remain the most promising class, with several having received Food and Drug Administration (FDA) approval (3) .  \nDespite signiﬁcant regulatory success, ICIs still face signiﬁcant challenges, including resistance, limited efﬁcacy, lack of reliable predictors of ICI response, non-durable beneﬁts, and toxicity (4–6) . Therefore, ongoing efforts to improving response rates and identifying new therapeutic targets have highlighted B7-H3, a member of the B7 family, as a promising candidate for immune checkpoint inhibition.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nB7 family  \nThe B7 family comprises struct","cbCaibYdDhkk3Qh6","https://ap.wps.com/l/cbCaibYdDhkk3Qh6","pdf",1823879,"English","# Introduction\n## B7 family\n## Structure and isoforms of mammalian B7-H3","[{\"question\":\"What role does the B7 family play in immune regulation?\",\"answer\":\"The B7 family provides costimulatory or coinhibitory signals that act as “second signals” in the two-signal model for naïve lymphocytes. They tune lymphocyte activation to shape the final immune response and maintain immune homeostasis.\"}]","B7-H3 (CD276) - an actionable therapeutic target and prognostic biomarker across human malignancies | PDF",1790154366,48,[139,143,147,151],{"page_no":22,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa263c0edd171fa973d0fb7627ad57eb.webp",983,1389,{"page_no":26,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80e2251ca342bf5cc34e0c0ac7b169b5.webp",982,1388,{"page_no":30,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/306c03cf26c5fe32a123c22030f2b2d2.webp",981,1386,{"page_no":33,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f0b9bbc4381acb40b00958fab592e37.webp",980,1385]